Ibrutinib (PCI-32765)
≥98%
- Product Code: 62943
CAS:
936563-96-1
| Molecular Weight: | 440.50 g./mol | Molecular Formula: | C₂₅H₂₄N₆O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Ibrutinib is primarily used in the treatment of certain types of cancers, particularly those affecting the blood and lymph nodes. It is highly effective in managing chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The drug works by inhibiting Bruton's tyrosine kinase (BTK), an enzyme crucial for the survival and proliferation of malignant B-cells. This targeted approach helps to slow down or stop the progression of these cancers. Additionally, ibrutinib is used in treating Waldenström's macroglobulinemia, a rare type of non-Hodgkin lymphoma. Its ability to selectively target cancer cells while sparing healthy cells makes it a valuable option in oncology, offering improved outcomes and reduced side effects compared to traditional chemotherapy.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to off-white solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | $13.06 |
+
-
|
| 0.050 | 10-20 days | $14.57 |
+
-
|
| 0.250 | 10-20 days | $32.14 |
+
-
|
| 1.000 | 10-20 days | $99.45 |
+
-
|
| 5.000 | 10-20 days | $451.53 |
+
-
|
| 25.000 | 10-20 days | $1,807.63 |
+
-
|
Ibrutinib (PCI-32765)
Ibrutinib is primarily used in the treatment of certain types of cancers, particularly those affecting the blood and lymph nodes. It is highly effective in managing chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The drug works by inhibiting Bruton's tyrosine kinase (BTK), an enzyme crucial for the survival and proliferation of malignant B-cells. This targeted approach helps to slow down or stop the progression of these cancers. Additionally, ibrutinib is used in treating Waldenström's macroglobulinemia, a rare type of non-Hodgkin lymphoma. Its ability to selectively target cancer cells while sparing healthy cells makes it a valuable option in oncology, offering improved outcomes and reduced side effects compared to traditional chemotherapy.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :